Glycenor-M
Generic Name
Gliclazide + Metformin Hydrochloride
Manufacturer
Healthcare Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Description
Overview of the medicine
Glycenor-M is a combination oral antidiabetic medication containing Gliclazide (a sulfonylurea) and Metformin Hydrochloride (a biguanide), used to manage type 2 diabetes mellitus when diet, exercise, and either drug alone do not provide adequate glycemic control.
Uses & Indications
Dosage
Adults
Initially 1 tablet once or twice daily with meals, adjusted based on glycemic control and tolerability. Max daily dose of Gliclazide 320 mg and Metformin 2500 mg (in divided doses).
Elderly
Start with lower doses and titrate carefully, especially considering renal function.
Renal_impairment
Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustment required for moderate impairment.
How to Take
Take orally with meals to reduce gastrointestinal side effects and improve absorption.
Mechanism of Action
Gliclazide stimulates insulin secretion from pancreatic beta cells. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Pharmacokinetics
Onset
Gliclazide: 1-2 hours. Metformin: Several days for full effect.
Excretion
Gliclazide: Primarily via urine as metabolites. Metformin: Excreted unchanged in the urine.
Half life
Gliclazide: 8-20 hours. Metformin: 4-9 hours.
Absorption
Gliclazide is readily absorbed from the GI tract. Metformin is slowly and incompletely absorbed from the GI tract.
Metabolism
Gliclazide is extensively metabolized in the liver. Metformin is not metabolized in the liver.
Side Effects
Contraindications
- •Hypersensitivity to Gliclazide, Metformin, or sulfonylureas
- •Type 1 diabetes
- •Diabetic ketoacidosis
- •Severe renal impairment (eGFR <30 mL/min/1.73m²)
- •Severe hepatic impairment
- •Acute or chronic metabolic acidosis
- •Dehydration, acute heart failure, septicemia, or other conditions predisposing to lactic acidosis
Drug Interactions
Alcohol
Increases risk of lactic acidosis (with Metformin) and hypoglycemia (with Gliclazide).
Diuretics
Thiazide diuretics may worsen glycemic control.
Cimetidine
May increase Metformin levels.
Beta-blockers
May mask symptoms of hypoglycemia.
Corticosteroids
May reduce the blood glucose lowering effect.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms include severe hypoglycemia and lactic acidosis. Management involves supportive care, glucose administration for hypoglycemia, and immediate medical attention for lactic acidosis.
Pregnancy & Lactation
Not recommended during pregnancy (insulin is preferred). Metformin passes into breast milk, Gliclazide excretion in milk is unknown. Consult doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date.
Availability
Pharmacies, hospitals, clinics
Approval Status
Approved
Patent Status
Generic available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
